US 11,667,892 B2
Human brown adipose derived stem cells and uses
Francisco Javier Silva, Melville, NY (US)
Assigned to BIORESTORATIVE THERAPIES, INC., Melville, NY (US)
Filed by BioRestorative Therapies, Inc., Melville, NY (US)
Filed on Feb. 2, 2021, as Appl. No. 17/165,074.
Application 17/165,074 is a division of application No. 16/183,370, filed on Nov. 7, 2018, granted, now 10,941,383.
Application 16/183,370 is a continuation of application No. 14/255,595, filed on Apr. 17, 2014, granted, now 10,167,449, issued on Jan. 1, 2019.
Claims priority of provisional application 61/906,087, filed on Nov. 19, 2013.
Claims priority of provisional application 61/813,771, filed on Apr. 19, 2013.
Prior Publication US 2021/0171914 A1, Jun. 10, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 5/0775 (2010.01); C12N 5/077 (2010.01); A61K 35/28 (2015.01); C12N 15/85 (2006.01); G01N 33/50 (2006.01)
CPC C12N 5/0667 (2013.01) [A61K 35/28 (2013.01); C12N 5/0653 (2013.01); C12N 15/85 (2013.01); G01N 33/5073 (2013.01); C12N 2510/04 (2013.01); G01N 2500/10 (2013.01)] 13 Claims
 
1. An implantable construct comprising:
a scaffold; and
a human neonatal brown adipose tissue differentiated cell derived from an isolated human neonatal brown adipose tissue stem cell;
wherein the isolated human neonatal brown adipose tissue stem cell is grown in a culture medium comprising fibronectin type III domain-containing protein 5 (FNDC5) and differentiates into the human neonatal brown adipose tissue differentiated cell; and
wherein UCP-1, ELOVL3, and PGC1A gene expression is upregulated in the human neonatal brown adipose tissue differentiated cell.